[Articles] Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial | ClinicLens
Duvakitug showed significant evidence for endoscopic response versus placebo in patients with moderately to severely active Crohn's disease, with no safety concerns identified.
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.